HIV Prevention

HIV+Hep estimates HIV cases averted & cost savings due to long-acting PrEP

“We must make sure that everyone with a reason to be on PrEP is able to access the medication best suited to their needs. With new long-acting PrEP, many people who have had a hard time adhering to a regimen of a daily pill now have another option to prevent HIV,” said Carl Schmid, executive director of the HIV+Hepatitis Policy Institute. “And we now know that more cases of HIV can be averted and medical costs can be saved by gradually increasing the uptake of long-acting PrEP. This must be taken into account as we develop policies and programs regarding the use and coverage of PrEP.”

read more

House votes signal strong opposition to domestic HIV funding cuts

Recent votes by the U.S. House of Representatives that unsuccessfully sought to cut domestic HIV programs offer a clear signal that even a wide majority of the House reject domestic HIV funding cuts. Yesterday, the House overwhelmingly rejected an amendment to the Labor, HHS appropriation bill that would have eliminated the HHS Minority HIV/AIDS Fund by a vote of 109 to 324.  On that vote, more Republicans (110) voted against the amendment than for it. An amendment to cut AIDS research at the NIH was made in order by leadership but ultimately was never offered.

read more

From the office of Massachusetts Senate President Karen E. Spilka: Senate passes bill expanding access to HIV prevention drug

“For the first time since PrEP became available eleven years ago, over a third of the people CDC believes could benefit from being on PrEP are being prescribed it. However, there are stark and widening racial, ethnic, and gender disparities in PrEP use in Massachusetts and nationwide,” said Kevin Herwig, Health Policy Manager at HIV+Hepatitis Policy Institute. “Allowing pharmacists to prescribe PrEP, as well as to link people with PrEP clinical services and HIV testing, will help remove barriers to getting HIV preventive medication for people and communities who have not yet been able to benefit from the promise of PrEP.  We thank the Senate, Senate President Spilka, Senator Cyr, and others for supporting this important legislation.”

read more

New CDC PrEP data demonstrates importance of federal funding

“While the data demonstrate progress in PrEP usage, which will translate into fewer new HIV transmissions, the low usage of PrEP among the communities most impacted by HIV points to the need for increased and targeted federal resources,” said Carl Schmid, executive director of the HIV+Hepatitis Policy Institute. “Unfortunately, House Republicans have proposed to cut $220 million from CDC’s HIV prevention program and completely eliminate HRSA’s $157 million PrEP program for community health centers. If these cuts were to be realized, instead of reporting on progress, the nation will be experiencing increased new HIV transmissions, which in the long run will cost us more.”

read more

Insurer responds to HIV discrimination complaint by lowering patient costs for drugs

Months after the HIV+Hepatitis Policy Institute and the North Carolina AIDS Action Network filed discrimination complaints against Blue Cross and Blue Shield of North Carolina for placing almost all HIV drugs on the highest drug tiers, the insurer has released a new mid-year drug formulary that leaves not a single HIV drug on the highest and most costly drug tiers. Instead of 48 HIV drugs, including many generics, on Tiers 5 and 6, there are now none.  As a result, depending on the plan, patients will be paying more reasonable and affordable costs.

read more

Pin It on Pinterest